- Home
- BYRN vs ALEC Comparison
BYRN vs ALEC Comparison
Compare BYRN & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BYRN | ALEC |
|---|---|---|
| Founded | 2005 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 311.6M | 262.7M |
| IPO Year | 2013 | 2019 |
Fundamental Metrics
Financial Performance| Metric | BYRN | ALEC |
|---|---|---|
| Price | $8.89 | $2.02 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $34.67 | $4.83 |
| AVG Volume (30 Days) | 313.0K | ★ 718.7K |
| Earning Date | 04-09-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.40 | N/A |
| Revenue | $16,566,295.00 | ★ $21,045,000.00 |
| Revenue This Year | $18.33 | $18.36 |
| Revenue Next Year | $17.23 | N/A |
| P/E Ratio | $22.63 | ★ N/A |
| Revenue Growth | ★ 1692.08 | N/A |
| 52 Week Low | $8.85 | $0.87 |
| 52 Week High | $33.56 | $3.40 |
Technical Indicators
Market Signals| Indicator | BYRN | ALEC |
|---|---|---|
| Relative Strength Index (RSI) | 28.17 | 44.21 |
| Support Level | N/A | $1.87 |
| Resistance Level | $21.98 | $2.02 |
| Average True Range (ATR) | 0.50 | 0.14 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 8.10 | 5.74 |
Price Performance
Historical ComparisonAbout BYRN Byrna Technologies Inc.
Byrna Technologies Inc is a designer, manufacturer, retailer, and distributor of technological solutions for security situations that do not require the use of lethal force. The company generates its revenue from the United States, South Africa, Europe, South America, Asia, and Canada.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.